BLACK WEEKSViaalid −15% · komplektid −10% · muu −5%koodigaTasuta tarne Saksamaal alates €200

See leht on tõlgitud automaatselt ja võib sisaldada vigu. Kas eesti keel on sinu emakeel? Ootame hea meelega sinu tagasisidet ja parandusi.Saada tagasisidet

The Peptide Desk The Peptide Desk
Ostarine (MK-2866), toote foto
SARMs

Ostarine (MK-2866)

SARMs

  • Saadetakse Saksamaalt

Tellimus

Ühiku hind - Black Weeksi ajal tasuta tarne Saksamaal alates 200 €
  • DHL koos jälgimisega
  • Diskreetne pakend

4.6 5-st Trustpilotis73 arvustust

Otsitud ka nimega: Ostarin

Lühidalt

Ostarine (MK-2866) arvudes

Põhinäitajad meie leksikonist. Lohista punkti mööda kõverat, et näha, kui palju jääb pärast ühte annust arvutuslikult alles.

Täielik leksikoni artikkel

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~24 hours

Half-life ~24 hours
After 48 hours: 25 %
Hour 2450 %Hour 4825 %Hour 7212.5 %Hour 1203.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

approx.24hours

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
25 mg1 size in the shop

Ostarine (MK-2866) jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid

Teadmised

Kõik teemal Ostarine (MK-2866)

FAQ

Korduma kippuvad küsimused

Allikad iga vastuse juurde: leksikoni artikkel

Kas sul on veel küsimusi?

Kirjuta meile, meie meeskond aitab sind.

What is ostarine?

Ostarine, also enobosarm or MK-2866, is a non-steroidal modulator of the androgen receptor (SARM). It was developed against muscle wasting and is meant to act mainly in muscle and bone. It is not approved, the highest stage was phase 3.

What did the study in healthy older adults show?

120 men over 60 and postmenopausal women received placebo or one of four levels for 12 weeks. At the higher level fat-free mass rose by 1.3 kg more than on placebo, fat fell by about 0.6 kg and weight stayed the same. Stair climbing got faster and insulin resistance fell by 27.5 percent. Side effects were as frequent as on placebo.

And in cancer patients?

In a phase 2 trial with 159 cancer patients with weight loss median fat-free mass rose by 1.5 kg (lower level) and 1.0 kg (higher level), on placebo by 0.02 kg. According to the trial the most common serious events were not related to the drug.

What happens to blood lipids and hormones?

HDL cholesterol fell by 17 and 27 percent. The binding protein SHBG fell by 61 percent in men and 80 percent in women. Total testosterone fell in men as well. Free testosterone did not change significantly.

What did the highest study dose show?

A trial in 136 women with advanced breast cancer had two levels, the higher at 18 mg per day. After 24 weeks 29 to 32 percent had a clinical benefit (response or stable disease). Serious side effects caused by the drug occurred in 8 and 16 percent, mainly raised liver enzymes, too much calcium in the blood and fatigue.

Are trials still running?

Yes. As of 26 October 2026 a phase 2 trial with 239 participants is running that tests weight and body function on semaglutide. A first trial on this with 168 participants is completed. Two phase 3 trials in lung cancer ended in 2013.

Võrdlused

Kuidas see võrdub

Seotud

Seotud tooted